Literature DB >> 2682593

Actions and interactions of psychotropic drugs on human performance and mood: single doses of ORG 3770, amitriptyline, and diazepam.

M Mattila1, M J Mattila, M Vrijmoed-de Vries, T Kuitunen.   

Abstract

Actions and interactions of two antidepressants and diazepam on human skilled performance and mood were studied in a randomized double-blind cross-over trial with single oral doses of 50 mg amitriptyline (AMI), 15 mg Org 3770 (ORG) and placebo, given alone and in combination with 15 mg diazepam (DZ) to 12 young healthy subjects at one-week intervals. Objective tests (digit substitution, tapping, flicker fusion, Maddox wing, tracking, choice reactions, body sway, memory) and subjective assessments (visual analogue scale) were performed at baseline and 1.5, 3, 4.5 and 6 hours after drug administration. Side-effects were reported, blood pressure and heart rate measured and blood samples taken after each testing run. Placebo was nearly inert on performance and mood. DZ impaired some objective skills and showed sedative effects in the subjective tests. AMI produced sedation and impaired coordination as well as cognitive performance (digit substitution), most clearly at 3 to 4.5 hr. ORG resembled AMI in impairing objective and subjective performance, however, not necessarily in the same tests. Their combined effects with DZ were additive in objective tests but less additive in subjective tests. The drug combinations, but not any single drug, impaired learning acquisition. Plasma concentrations of the drugs given alone were about as expected, without important interactions. We conclude that the combinations of benzodiazepines with the antidepressants used impair skilled performance but may not cause major hazards.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2682593     DOI: 10.1111/j.1600-0773.1989.tb01132.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  8 in total

1.  Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.

Authors:  R Davis; M I Wilde
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

Review 2.  Mirtazapine: a review of its use in major depression.

Authors:  K J Holm; A Markham
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of mirtazapine.

Authors:  C J Timmer; J M Sitsen; L P Delbressine
Journal:  Clin Pharmacokinet       Date:  2000-06       Impact factor: 6.447

Review 4.  A risk-benefit assessment of mirtazapine in the treatment of depression.

Authors:  S Kasper; N Praschak-Rieder; J Tauscher; R Wolf
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

5.  Amitriptyline, clovoxamine and cognitive function: a placebo-controlled comparison in depressed outpatients.

Authors:  B Spring; A J Gelenberg; R Garvin; S Thompson
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine.

Authors:  M J Mattila; K Aranko; T Kuitunen
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

7.  Cognitive decline with nortriptyline use in a patient with dementia of the Alzheimer's type.

Authors:  P Bartlomé; K S King; F Matsuo; J S Wood
Journal:  West J Med       Date:  1992-01

8.  Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype.

Authors:  Johannes G Ramaekers; Silke Conen; Pieter Jan de Kam; Sabine Braat; Pierre Peeters; Eef L Theunissen; Neely Ivgy-May
Journal:  Psychopharmacology (Berl)       Date:  2011-01-19       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.